Financials
Financial year 2025
PHARMENFORM from Koekelberg, company number BE0806031594, closed financial year 2025 with a result of € 54,895 after tax. For that financial year PHARMENFORM recorded a gross margin of € 457,294 and equity of € 234,833. Compared with financial year 2024, the result moved from € 65,735 to € 54,895. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 234,833
▼ 32% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 54,895
▼ 16% vs 2024
Profit after tax over the fiscal year.
€ 86,761
▲ 42% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 166,029 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
3.9
▼ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 343,246
▼ 2% vs 2024
€ 88,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 28,507
▼ 44% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 69,837
▼ 27% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 48,624
▼ 23% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 449,361 | € 382,279 | € 491,756 | € 457,294 | ▼ 7% |
| Profit after taxes | € 99,241 | € 47,957 | € 65,735 | € 54,895 | ▼ 16% |
| Equity | € 256,553 | € 280,232 | € 345,967 | € 234,833 | ▼ 32% |
| Total debts | € 359,541 | € 282,481 | € 199,114 | € 333,004 | ▲ 67% |
| Cash | € 126,315 | € 48,864 | € 61,006 | € 86,761 | ▲ 42% |
| Land & buildings | € 4,742 | € 4,254 | € 3,765 | € 3,277 | ▼ 13% |
| Retained profit | € 237,953 | € 261,632 | € 327,367 | € 216,233 | ▼ 34% |
| Dividend | € 45,000 | € 24,278 | € 0 | € 166,029 | |
| Balance sheet total | € 616,094 | € 562,713 | € 545,081 | € 567,837 | ▲ 4% |
| Employees (FTE) | 3.5 | 3.3 | 4.2 | 3.9 | ▼ 0.3 |
Key figures of PHARMENFORM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMENFORM?
What happened at PHARMENFORM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 54,895 (▼ 16% vs 2024). Source: NBB ↗
- New establishment in Sint-Jans-Molenbeek. KBO
- New establishment in Koekelberg. KBO
- Start of the company according to the CBE. KBO
In short
From € 99,241 profit in 2022 to € 54,895 profit in 2025.
Paid € 102,794 in corporate taxes since 2022.
Best year ever: 2022, with € 99,241 profit.
On average € 117,300 of value added per employee in 2025.
A new publication or filing at PHARMENFORM? We notify you, reason included.
Follow PHARMENFORMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMENFORM are SIMON HAVAUX VINCENT and MARIE GOOSKENS JANIQUE.
Directors
According to the 2025 annual accounts
SIMON HAVAUX VINCENT
Director
MARIE GOOSKENS JANIQUE
Director
Establishments
Establishment units
Physical locations of this company
Eugène Simonisplein 1
1081 Koekelberg
Leopold II laan 136
1080 Sint-Jans-Molenbeek
Active since 1 October 2020
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
COMBELL-AS, BE
Website info
Features
Security
Details
- Company number
- 0806.031.594
- VAT number
- BE 0806.031.594
- Registered office
- Eugène Simonisplein 1, 1081 Koekelberg
- Names & denominations
- PHARMENFORM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 August 2008
- Peppol
- Active · Active since 11 Dec 2025
- Contact
- pharmenform.be
- Activities · NACE
Detailhandel in farmaceutische producten
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels